Ihtsham Ul Haq, MD

Dr. Ihtsham ul Haq is Professor of Neurology and Chief of Movement Disorders Division. His passion for the study of the brain began at Columbia University, at which he completed degrees in Bioengineering and in Philosophy. He obtained his medical degree at SUNY Downstate and his Neurology residency training at Georgetown University. After his residency he spent three years at the University of Florida’s Movement Disorders & Neurorestoration program at the Norman Fixel Institute for Neurological Diseases performing his movement disorders fellowship training. He was previously Associate Professor at the Wake Forest School of Medicine in the Departments of Neurology and Neurosurgery before taking his current position at UM. Highlights of his tenure at WFSM include bringing it into the NIH clinical trial research consortium (NeuroNext). His areas of expertise are Movement Disorders, Tremor, Parkinson’s disease, Parkinson’s-plus syndromes (Lewy Body Dementia, Corticobasal Degeneration, Progressive Supranuclear Palsy, Multiple Systems Atrophy), Dystonia, Essential Tremor, Tourette syndrome (adults), Ataxia, Chorea, non-epileptic myoclonus, and Deep Brain Simulation (DBS).

Dr. Haq is a fellow of the American Academy of Neurology and was selected to its Emerging Leaders Program in 2015. He currently serves on the AAN’s Division Chief subcommittee. Dr. Haq is also a member of the International Movement Disorders Society and Parkinson’s Study Groups.


Research Interests

His overall research interest has been in understanding and improving the care of patients with movement disorders, with a focus on technology and brain circuitry. He has been funded by the National Institute of Health, Parkinson’s Foundation, and Smallwood Foundation, as well as partnering with industry to bring better treatments to patients. His NIH funded research has included work on both common (Parkinson’s & Alzheimer’s disease) and rare disorders (A TP1A 3 post-infancy onset dystonia syndrome, or Rapid-onset Dystonia Parkinsonism). He has been performing Deep Brain Stimulation (DBS) surgeries since 2006 and has been part of pioneering efforts to improve targeting, increase the types of devices available to patients, and expand the number of diseases that treated by the technique. In addition to using DBS to treat Parkinson’s disease, Essential Tremor, and Dystonia, he has used it to treat patients with medication-refractory Tourette’s syndrome and Obsessive-Compulsive Disorder. Dr. Haq has also worked to advance the success of clinical trials, and shortly after being selected to the NIH Clinical Trial Methodology Course in 2017, served as the CoPI of the Wake Forest site for the NIH Network for Excellence in Neuroscience Clinical Trials (NeuroNext).

The UM Movement Disorders Division is now participating in more than 30 industry, NIH, and foundation-funded studies. With respect to DBS, UM implanted more than 90 leads this past year and were part of the pivotal trials for both Boston Scientific and Abbott’s DBS devices. Dr. Haq and the Division have also made it a focus to take concrete steps to ensure historically underrepresented patients are provided that opportunity to participate in research at UM, including pipeline programs, advocacy, and disparity research.


Education & Training

2002: SUNY Downstate Health Science Center , Brooklyn, NY

MD, Neurology

1998: Columbia University, New York City

BA, Philosophy

1997: Columbia University School of Engineering, New York City

BS, Bioengineering

Post Graduate Training

2009: Shands Hospital, UF, Gainesvile FL

Fellowship, Movement Disorders

2006: Georgetown University Hospital, Washington, D.C.

Residency, Neurology

2003: Staten Island University Hospital, Staten Island, NY

Internship, Internal Medecine

Licensures and Certifications

American Board of Psychiatry and Neurology


Tatjana Rundek, MD, PhD, FANA

Tatjana Rundek, M.D., Ph.D., is a vascular and cognitive neurologist, clinical researcher and leader of several programs and projects on determinants of stroke, age-related memory loss, cognitive decline and brain health. She serves as a professor of neurology, executive vice chair of research and faculty affairs, and director of the University of Miami Miller School of Medicine Department of Neurology Clinical Translational Research Division in Florida. She also is director of the Evelyn F. McKnight Brain Institute at the University of Miami.


Dr. Rundek completed a neurology and research fellowship at Columbia University in New York City. She was the first Fulbright Scholar at the Neurological Institute of New York – Columbia University Irving Medical Center.


Dr. Rundek is a collaborative scientist-investigator with over 550 peer-reviewed publications, editorials and book chapters. She has extensive research networks with multiple national and international research teams, including investigators from Columbia University on large National Institutes of Health (NIH)-funded population-based studies of age-related neurovascular disease and the Einstein Aging Study on vascular cognitive decline. She serves as a team scientist-leader of large international stroke and aging projects and consortia, including the National Institute on Aging (NIA)-funded Precision Aging Network.


Dr. Rundek is a dedicated educator and mentor who leads educational and mentorship programs. She serves as training director of two large National Institute of Neurological Disorders and Stroke-funded clinical trial networks, StrokeNet and NeuroNEXT. She is director of the NIA-funded 1Florida Alzheimer’s Disease Research Center Research Education Program and director of the University of Miami master of science in clinical translational investigation program and the K12 mentored career development research training program at the University of Miami Clinical Translational Science Institute. She was a recipient of an American Heart Association Mentor Award and an NIH K24 research training and career development grant.


Dr. Rundek has been an active member of a broader professional and scientific community. She is a section editor of Stroke for Brain Health and serves on the editorial boards of several influential scientific journals, including Neurology, Journal of Ultrasound in Medicine and Cerebrovascular Diseases. She also serves on the NIH and other professional organizations’ grant review study sections. She is a fellow of the American Heart Association (AHA) and American Academy of Neurology. She is immediate past president of the Intersocietal Accreditation Commission Vascular Testing Board of Directors, a U.S. organization that accredits clinical nuclear, PET, MRI, CT, ultrasound and carotid stenting programs. Dr. Rundek is past president of the Neurosonology Communities of Practice of the American Institute in Ultrasound in Medicine, the largest professional medical ultrasound organization in the U.S. In Florida, she serves on the AHA South Florida board and is a recipient of the prestigious AHA Cor Vitae for Stroke Award, In the Company of Women Outstanding Woman in Science and Technology Miami-Dade Award, and the Women in Academic Medicine Career Achievement Award. In 2022, she was elected to the Academy of Science, Engineering & Medicine of Florida





Bonnie E. Levin, PhD

Dr. Bonnie Levin is the Schoninger/Goldberg Professor of Neurology and Director of the Division of Neuropsychology and Cognitive Neuroscience in the Department of Neurology at Miller School of Medicine. She is a neuropsychologist whose research examines neurocognitive and affective changes associated with neurodegenerative disease and the normative aging process. Her work focuses on the intersection of physical, behavioral and sensory changes that take place over the life course, and identifying markers of atypical aging associated with cognitive decline. She explores trajectories of cognitive aging, the underlying neural circuitry, and other biological markers associated with increased risk of cognitive decline. Her data has direct application toward developing timely early interventions for those carrying one or more risk factors as well as for those individuals who strive to age in place and engage in practices that promote healthy aging.

Dr. Levin has received federal and state funding to examine the role of vascular and metabolic risk factors predictors of cognition and how differential markers of physical frailty, emotional dysregulation and sensory change increase the risk of cognitive decline. Other projects include: examining which components of the metabolic syndrome predict cognition, identifying imaging and clinical correlates of white matter changes associated with the aging process and linking structural and metabolic markers underlying different symptom profiles in neurodegenerative disease, defining profiles of risk and resilience in aging, examining the basis of impaired decision making among the elderly, and operationalizing brain fog in long covid.

Schoninger Neuropsychology Program- The Alexandria and Bernard Schoninger Neuropsychology Program was established in 2009 as part of the Evelyn McKnight Brain Institute. Dr. Levin was awarded the Alexandra and Bernard Schoninger Endowed Professorship, which afforded her the opportunity to establish a program that provides comprehensive testing for individuals experiencing memory loss. One of the major aims is to collect data on cardiometabolic risk factors in order to characterize cognitive change associated with the aging process and to define the earliest markers that signal cognitive decline. Each patient who is evaluated will also be a participant in a research registry sponsored by the Evelyn McKnight Brain Institute. This registry has served as an invaluable resource for numerous publications and pilot data for grant applications that support the McKnight Brain Institute’s objectives.

Education and Mentorship

In l989, Dr. Levin initiated the UM Neurology Advanced Training Practicum. At the same time, the Neuropsychology Post-doctoral Fellowship program was initiated. Currently, there are four post-doctoral fellows and six upper level graduate PhD practicum students, and two volunteer undergraduate assistants. Over the past 34 years, she has mentored hundreds of students, interns, residents and fellows. In addition, she leads weekly neuropsychology rounds which are attended by undergraduate and graduate students, post doctoral fellows, neurology residents and faculty, and trainees from other departments, including Psychiatry, Public Health and Sylvester Cancer Center. Dr. Levin has taught the Foundations of Neuropsychology since l989 at the Coral Gables Campus. It remains, to date, the only graduate doctoral level course in neuropsychology offered at UM. This course attracts graduate students from all of the clinical tracks (Child, Adult and Behavioral Medicine).

Dr. Levin’s work is highly collaborative. She actively collaborates with faculty in other departments, including Radiology, Neurosurgery, Psychiatry, Pediatrics, Medicine, Ophthalmology, and Epidemiology and Public Health.

Community Outreach

Dr. Levin is involved in community outreach in the State of Florida. Most recently , she was funded to examine the epidemic of scamming among vulnerable elders and she developed a training intervention to decrease susceptibility to deception. Her pilot study has been successfully launched in English and Spanish and designed to reach the most vulnerable in the Miami community. In addition, a UF-UCF- UM Consortium Project funded by FL DOH, in which Dr. Levin is the PI for UM, is a state wide study to examine the cognitive and imaging markers of scam susceptibility is also underway.

In addition to Dr. Levin, several members of the Division of Neuropsychology and Cognitive Neuroscience, Drs. Annelly Bure, Marina Sarno and Katalina McInerney are forging strong community ties with the Latino Center on Aging. They are regular speakers at community gatherings and on radio talk shows and address a wide range of topics on brain health.

Future Goals

Dr. Levin plans to expand the Schoninger Neuropsychology Program in several directions, all of which promote the strategic plan. First, the Mcknight registry will be expanded to enhance the neurologic, vestibular, kinesthesia, and sensory assessment. This multi-disciplinary data base will serve as a resource for other researchers in the field of aging and, in particular, foster interdepartmental collaboration. It will also provide critical pilot data needed for federal and state funding for future research.

Second, the post doctoral and practicum training sites will be expanded to incorporate dedicated research training. Each post doctoral fellow will be mentored in developing their research interests in the field of aging, working closely under supervision with a faculty member based in the Division of Neuropsychology and Cognitive Neuroscience.

Third, grant applications will be prioritized to foster inter-departmental collaborations at UM and other Mcknight sites. Dr. Levin has worked on the MBAR project since its inception and led the cognitive work group in developing the neuropsychological test battery. She plans to continue leading this effort to the next step towards federal funding. In addition, she continues to work directly with Dr. Rundek on the NOMAS and plans to apply to funding to operationalize specific covid outcomes including brain fog. She is also exploring writing a PCORI grant.

Fourth, Dr. Levin has will work diligently toward expanding community involvement efforts. Several presentations are planned to encourage greater interaction with Hispanic and non-Hispanic individuals residing in the community. Closer relationships with community leaders are integral to disseminating information that educate elders on healthy aging and resilience as well as promoting the importance of research participation.